Novavax (NVAX) reportedly plans to file for U.S. approval of its coronavirus vaccine candidate in December. NVAX stock wavered on the news.
Chief Executive Stanley Erck announced the company’s intentions in an interview with Czech daily Hospodarske Noviny published Thursday, according to Reuters. Novavax in May acquired a manufacturing facility in Bohumil, Czech Republic. There it plans to develop and manufacture some of its coronavirus vaccine candidate, NVX‑CoV2373.
NVAX stock seesawed between modest gains and losses on the stock market today. But shares tumbled late, ending the session down 6.3% at 107.35. A company spokesperson told IBD via email that a clarification of the CEO’s comments might be coming, but that had not happened as of 4:15 p.m. EDT.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE